Results 211 to 220 of about 70,073 (274)

Castration-Resistant Prostate Cancer: AUA Guideline

Journal of Urology, 2013
This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data.A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate ...
Michael S, Cookson, Bruce J, Roth, Philipp, Dahm, Christine, Engstrom, Stephen J, Freedland, Maha, Hussain, Daniel W, Lin, William T, Lowrance, Mohammad Hassan, Murad, William K, Oh, David F, Penson, Adam S, Kibel   +11 more
openaire   +2 more sources

Castration-Resistant Prostate Cancer: Targeted Therapies

Chemotherapy, 2011
<i>Background:</i> Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. <i>Objective:</i> To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. <i>
S, Leo, C, Accettura, V, Lorusso
openaire   +2 more sources

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

The Lancet Oncology, 2018
BACKGROUND Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed.
M. Hofman, J. Violet, R. Hicks, Justin Ferdinandus, S. Thang, T. Akhurst, A. Iravani, G. Kong, A. R. Ravi Kumar, D. Murphy, P. Eu, P. Jackson, M. Scalzo, S. Williams, S. Sandhu   +14 more
semanticscholar   +1 more source

Castrate-resistant prostate cancer: therapeutic strategies

Expert Opinion on Pharmacotherapy, 2010
Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies.This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors.The reader will ...
Andrea L, Harzstark, Eric J, Small
openaire   +2 more sources

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

The Lancet
BACKGROUND [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and ...
M. Morris, D. Castellano, Ken Herrmann, Johann S. de Bono, N. Shore, Kim N Chi, M. Crosby, J. Piulats, A. Fléchon, Xiaoyuan Wei, H. Mahammedi, G. Roubaud, H. Študentová, James Nagarajah, Begoña Mellado, Á. Montesa-Pino, E. Kpamegan, S. Ghebremariam, T. N. Kreisl, C. Wilke, K. Lehnhoff, O. Sartor, K. Fizazi   +22 more
semanticscholar   +1 more source

Overcoming castration resistance in prostate cancer

Current Opinion in Urology, 2012
Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify ...
Che-Kai, Tsao, Alexander C, Small, Matthew D, Galsky, William K, Oh   +3 more
openaire   +2 more sources

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.

European Urology, 2020
BACKGROUND Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time.
B. Feuerecker, R. Tauber, K. Knorr, M. Heck, A. Beheshti, C. Seidl, F. Bruchertseifer, A. Pickhard, A. Gafita, C. Kratochwil, M. Retz, J. Gschwend, W. Weber, C. D’Alessandria, A. Morgenstern, M. Eiber   +15 more
semanticscholar   +1 more source

Immunotherapy for Castration-Resistant Prostate Cancer

Urologic Clinics of North America, 2012
The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach. Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation.
Guru, Sonpavde, Philip W, Kantoff
openaire   +2 more sources

New developments in castrate‐resistant prostate cancer

BJU International, 2012
Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease.
Shore, N., Mason, M., de Reijke, Th M.
openaire   +2 more sources

Molecular Mechanisms of Castrate-Resistant Prostate Cancer

Urologic Clinics of North America, 2022
Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in CRPC have been identified.
Srinath, Kotamarti, Andrew J, Armstrong, Thomas J, Polascik, Judd W, Moul   +3 more
openaire   +2 more sources